These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 34963694

  • 1. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing.
    Ferguson DC, Momeni Boroujeni A, Zheng T, Mohanty AS, Ho AL, Arcila ME, Ross DS, Dogan S.
    Mod Pathol; 2022 Jul; 35(7):895-902. PubMed ID: 34963694
    [Abstract] [Full Text] [Related]

  • 2. Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays.
    Robinson CL, Harrison BT, Ligon AH, Dong F, Maffeis V, Matulonis U, Nucci MR, Kolin DL.
    Mod Pathol; 2021 Mar; 34(3):603-612. PubMed ID: 33077919
    [Abstract] [Full Text] [Related]

  • 3. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS, Bowman AS, Zehir A, Razavi P, Brogi E, Ladanyi M, Arcila ME, Wen HY, Ross DS.
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [Abstract] [Full Text] [Related]

  • 4. HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
    Xia D, Kuo F, Hughes M, Lindeman N, Manning D, Files J, Strauss S, Kirkner G, Mohammed-Abreu A, Winer E, Tolaney SM, Lin NU, Dillon DA.
    Am J Clin Pathol; 2024 May 02; 161(5):436-442. PubMed ID: 38104247
    [Abstract] [Full Text] [Related]

  • 5. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
    Chatzopoulos K, Collins AR, Sotiriou S, Keeney MG, Visscher DW, Rivera M, Schembri-Wismayer DJ, Lewis JE, Greipp PT, Sukov WR, Chintakuntlawar AV, Price KA, Garcia JJ.
    Head Neck Pathol; 2020 Dec 02; 14(4):951-965. PubMed ID: 32350809
    [Abstract] [Full Text] [Related]

  • 6. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
    Ichikawa H, Usui K, Aizawa M, Shimada Y, Muneoka Y, Kano Y, Sugai M, Moro K, Hirose Y, Miura K, Sakata J, Yabusaki H, Nakagawa S, Kawasaki T, Umezu H, Okuda S, Wakai T.
    BMC Cancer; 2024 Jun 11; 24(1):719. PubMed ID: 38862927
    [Abstract] [Full Text] [Related]

  • 7. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
    Cenaj O, Ligon AH, Hornick JL, Sholl LM.
    Am J Clin Pathol; 2019 Jun 05; 152(1):97-108. PubMed ID: 31115453
    [Abstract] [Full Text] [Related]

  • 8. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, Vranic S, Gatalica Z.
    Cancer Med; 2019 Dec 05; 8(17):7322-7329. PubMed ID: 31609094
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
    Christgen M, van Luttikhuizen JL, Raap M, Braubach P, Schmidt L, Jonigk D, Feuerhake F, Lehmann U, Schlegelberger B, Kreipe HH, Steinemann D.
    Oncotarget; 2016 Dec 13; 7(50):82733-82740. PubMed ID: 27716627
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
    Nakamura K, Aimono E, Oba J, Hayashi H, Tanishima S, Hayashida T, Chiyoda T, Kosaka T, Hishida T, Kawakubo H, Kitago M, Okabayashi K, Funakoshi T, Okita H, Ikeda S, Takaishi H, Nishihara H.
    Med Oncol; 2021 Mar 12; 38(4):36. PubMed ID: 33710417
    [Abstract] [Full Text] [Related]

  • 13. ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy.
    McAfee JL, Hoda RS, Hoyle C, McCoy L, Sprague C, Reddy CA, Koyfman SA, Geiger JL, Komforti MK, Griffith CC.
    Mod Pathol; 2023 Oct 12; 36(10):100273. PubMed ID: 37423585
    [Abstract] [Full Text] [Related]

  • 14. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R, Mulligan AM, Have C, O'Malley FP.
    Appl Immunohistochem Mol Morphol; 2007 Sep 12; 15(3):316-24. PubMed ID: 17721278
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
    Pfarr N, Penzel R, Endris V, Lier C, Flechtenmacher C, Volckmar AL, Kirchner M, Budczies J, Leichsenring J, Herpel E, Noske A, Weichert W, Schneeweiss A, Schirmacher P, Sinn HP, Stenzinger A.
    Genes Chromosomes Cancer; 2017 Apr 12; 56(4):255-265. PubMed ID: 27792260
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups.
    Yang SR, Bouhlal Y, De La Vega FM, Ballard M, Kuo CJ, Vilborg A, Jensen G, Allison K.
    Mod Pathol; 2020 Aug 12; 33(8):1546-1556. PubMed ID: 32161378
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.